NASDAQ:ARDS - Aridis Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $19.00
  • Forecasted Upside: 171.43 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.36 (5.42%)

This chart shows the closing price for ARDS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aridis Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARDS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARDS

Analyst Price Target is $19.00
▲ +171.43% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Aridis Pharmaceuticals in the last 3 months. The average price target is $19.00, with a high forecast of $22.00 and a low forecast of $17.00. The average price target represents a 171.43% upside from the last price of $7.00.

This chart shows the closing price for ARDS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Aridis Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/9/2021HC WainwrightReiterated RatingBuyLow
2/24/2021Northland SecuritiesReiterated RatingBuy$22.00High
2/23/2021Roth CapitalReiterated RatingBuyMedium
1/22/2021Roth CapitalReiterated RatingBuy$18.00High
12/7/2020Northland SecuritiesReiterated RatingBuy$22.00High
11/23/2020Northland SecuritiesReiterated RatingBuy$22.00High
8/13/2020Maxim GroupReiterated RatingBuy$17.00Low
6/23/2020Maxim GroupReiterated RatingBuy$17.00High
5/15/2020HC WainwrightReiterated RatingPositive ➝ Buy$7.00 ➝ $11.00High
5/5/2020Maxim GroupInitiated CoverageBuy$17.00High
4/10/2020Maxim GroupInitiated CoverageBuy$17.00High
4/9/2020Northland SecuritiesReiterated RatingBuy$22.00High
2/19/2020Roth CapitalInitiated CoverageBuy$18.00High
12/30/2019HC WainwrightInitiated CoverageBuy$7.00High
11/14/2019Northland SecuritiesReiterated RatingBuy$22.00Low
9/30/2019Northland SecuritiesSet Price TargetBuy$22.00Low
9/4/2019LaidlawSet Price TargetBuy$15.00Low
9/3/2019Maxim GroupSet Price TargetBuy$25.00Low
8/15/2019Maxim GroupReiterated RatingBuy$25.00High
8/13/2019Northland SecuritiesReiterated RatingBuy$40.00High
7/31/2019Maxim GroupReiterated RatingBuyHigh
7/30/2019Northland SecuritiesReiterated RatingBuy$40.00High
5/16/2019Maxim GroupSet Price TargetBuy$25.00Low
4/17/2019Northland SecuritiesReiterated RatingBuy$40.00Low
4/1/2019Maxim GroupReiterated RatingBuy$25.00High
3/29/2019Northland SecuritiesReiterated RatingBuy$40.00Low
1/9/2019Cantor FitzgeraldReiterated RatingBuy$25.00Medium
12/26/2018Cantor FitzgeraldReiterated RatingBuy$25.00High
12/12/2018Maxim GroupSet Price TargetBuy$25.00Low
12/4/2018Maxim GroupSet Price TargetBuy$25.00Low
11/13/2018Cantor FitzgeraldReiterated RatingBuy$25.00Low
11/13/2018Maxim GroupSet Price TargetBuy$25.00Low
10/2/2018Maxim GroupInitiated CoverageBuyMedium
9/10/2018Northcoast ResearchInitiated CoverageOutperform$40.00Low
9/10/2018Northland SecuritiesInitiated CoverageOutperformLow
9/10/2018LaidlawInitiated CoverageBuy$23.00Low
9/10/2018Cantor FitzgeraldInitiated CoverageOverweightLow
9/9/2018Cantor FitzgeraldInitiated CoverageBuy$25.00Low
(Data available from 6/21/2016 forward)
Aridis Pharmaceuticals logo
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.
Read More

Today's Range

Now: $7.00
Low: $6.50
High: $7.00

50 Day Range

MA: $6.14
Low: $5.30
High: $7.22

52 Week Range

Now: $7.00
Low: $4.70
High: $8.65


14 shs

Average Volume

24,666 shs

Market Capitalization

$78.63 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Aridis Pharmaceuticals?

The following Wall Street analysts have issued reports on Aridis Pharmaceuticals in the last twelve months: HC Wainwright, Maxim Group, Northland Securities, Roth Capital, and Zacks Investment Research.
View the latest analyst ratings for ARDS.

What is the current price target for Aridis Pharmaceuticals?

3 Wall Street analysts have set twelve-month price targets for Aridis Pharmaceuticals in the last year. Their average twelve-month price target is $19.00, suggesting a possible upside of 171.4%. Northland Securities has the highest price target set, predicting ARDS will reach $22.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $17.00 for Aridis Pharmaceuticals in the next year.
View the latest price targets for ARDS.

What is the current consensus analyst rating for Aridis Pharmaceuticals?

Aridis Pharmaceuticals currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ARDS will outperform the market and that investors should add to their positions of Aridis Pharmaceuticals.
View the latest ratings for ARDS.

What other companies compete with Aridis Pharmaceuticals?

How do I contact Aridis Pharmaceuticals' investor relations team?

Aridis Pharmaceuticals' physical mailing address is 5941 Optical Ct, San Jose CA, 95138. The company's listed phone number is (408) 385-1742 and its investor relations email address is [email protected] The official website for Aridis Pharmaceuticals is